Andrei Shustov
Chief Tech/Sci/R&D Officer at CELLECTAR BIOSCIENCES, INC.
Net worth: 219 047 $ as of 2024-03-30
Profile
Andrei Shustov is currently a Senior Vice President-Medical at Cellectar Biosciences, Inc. He previously worked as a Senior Medical Director-Late Stage Clinical at Seagen Inc. Shustov earned a doctorate degree from S.
I.
Georgievsky's Medical Academy in 1987.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-12-07 | 55,037 ( 0.45% ) | 219 047 $ | 2024-03-30 |
Andrei Shustov active positions
| Companies | Position | Start |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-02-14 |
Former positions of Andrei Shustov
| Companies | Position | End |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | - |
Training of Andrei Shustov
| S. I. Georgievsky's Medical Academy | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Andrei Shustov
